The rise of Sildenafil initially fueled significant growth in the drug sector, generating a perception of guaranteed returns. However, funding in companies heavily reliant on flagship drugs like the erectile dysfunction pill presents considerable challenges. Patent end has caused generic rivalry,

The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for blockbuster treatments and substantial returns is